Alunbrig (Brigatinib)

Brigatinib is a tyrosine kinase inhibitor used in the treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. 

 Recommended dosage: 

The recommended dosage of Alunbrig (Brigatinib) is 90 mg orally once daily for the first 7 days; then increase the dose to 180 mg orally once daily.  

Healthcare professionals recommend administering Alunbrig tablets orally via the mouth. One may take the tablets of Alunbrig with or without food. 

• Severe, life-threatening, and fatal pulmonary adverse reactions consistent with interstitial lung disease (ILD)/pneumonitis have occurred with Alunbrig. One should monitor for new or worsening respiratory symptoms, particularly during the first week of initiating Alunbrig.
• Hypertension was seen in the patients who are receiving Alunbrig. One should control blood pressure before treatment with Alunbrig. And one should monitor blood pressure after 2 weeks and at least monthly after that during treatment with Alunbrig.
• Grade 3 bradycardia occurred in the patients who were receiving Alunbrig. One should monitor heart rate and blood pressure during treatment with Alunbrig. And one should monitor patients more frequently if concomitant use of drugs known to cause bradycardia cannot be avoided. 
• Alunbrig can cause fetal harm when administered to pregnant women. There is no clinical data on the use of Alunbrig in pregnant women. Healthcare professionals advise females of reproductive potential to use effective non-hormonal contraception during treatment with Alunbrig and for at least 4 months following the final dose. One should advise males with female partners of reproductive potential to use effective contraception during treatment and at least 3 months after the last dose of Alunbrig. 

Urgent Meds is able to source the ALUNBRIG from across the globe and has the ability to supply. Urgent Meds offers its customers worldwide access to the best available treatment.

Urgent Meds is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Alunbrig®?

The generic name for the trade name drug Alunbrig® is Brigatinib.

What are the ingredients of the medicine Alunbrig®?

The active ingredient in the medicine is Brigatinib, with inactive ingredients including lactose monohydrate, microcrystalline cellulose, sodium starch glycolate (Type A), magnesium stearate, and hydrophobic colloidal silica.

Is Alunbrig® approved by the FDA?

Yes, Alunbrig® is approved by the FDA. Date of approval: April 28, 2017.

What is Alunbrig®?

Alunbrig® contains Brigatinib, a tyrosine kinase inhibitor with in vitro activity at clinically achievable concentrations against multiple kinases including ALK, ROS1, insulin-like growth factor-1 receptor (IGF-1R), and FLT-3 as well as EGFR deletion and point mutations.

What is the dosage and form of Alunbrig® supplied?

Alunbrig® is supplied as tablets: 180 mg, 90 mg, or 30 mg for oral administration.

What are the most common side effects due to Alunbrig®?

The most common side effects of Alunbrig® are diarrhea, fatigue, nausea, rash, cough, muscle pain, headache, high blood pressure, vomiting, and difficulty breathing.

How much does Alunbrig® cost in India?

The Alunbrig® cost in India is reasonably sensible. To authenticate this drug, you can call or WhatsApp +1-647-818-4196 or email info@urgentmeds.in.

How to store the medicine Alunbrig®?

One should store Alunbrig® at room temperature 20°C to 25°C (68°F to 77°F).

Is it safe to buy Alunbrig® online?

To buy Alunbrig® (Brigatinib) online, always look for an authentic, legitimate, WHO-GDP and ISO-certified Pharmaceutical Wholesaler/Distributor/Supplier.